NASDAQ: GNTAGenenta Science Spa Stock
$4.00-0.03 (-0.74%)
Updated Sep 12, 2024
GNTA Price
$4.00
Fair Value Price
$0.22
Market Cap
$72.87M
52 Week Low
$2.20
52 Week High
$5.87
P/E
-5.75x
P/B
3.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$12M
Beta
0.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNTA Overview
Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for the treatment of solid tumors. The company's lead product candidate is Temferon, in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta Science was incorporated in 2014 and is headquartered in Milan, Italy.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GNTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNTA ($4.00) is overvalued by 1,691.53% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNTA ($4.00) is not significantly undervalued (1,691.53%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNTA due diligence checks available for Premium users.
Be the first to know about important GNTA news, forecast changes, insider trades & much more!
GNTA News
Valuation
GNTA fair value
Fair Value of GNTA stock based on Discounted Cash Flow (DCF)
Price
$4.00
Fair Value
$0.22
Overvalued by
1,691.53%
GNTA ($4.00) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNTA ($4.00) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.75x
Industry
-185.79x
Market
24.41x
GNTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.28x
Industry
6.45x
GNTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNTA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GNTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$24.8M
Liabilities
$2.1M
Debt to equity
0.09
GNTA's short-term assets ($23.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNTA's short-term assets ($23.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GNTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNTA vs Biotech Stocks
Genenta Science Spa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.